Friday, May 24, 2013 Last update: 1:34 PM
Company Tech News as it Breaks
Avaxia Biologics, Inc.
News articles for Avaxia Biologics, Inc.:
Tuesday, March 26, 2013
- Avaxia Biologics Appoints Deborah S. Hartman, Ph.D. as Vice President, ResearchAvaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that Deborah S. Hartman, Ph.D. has joined the company as ... read more
Monday, February 25, 2013
- Avaxia Biologics Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative ColitisAvaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase ... read more
Tuesday, December 18, 2012
- Avaxia Biologics Raises $6.4 Million in Series B FinancingAvaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company raised $6.4 million in a Series B ... read more
Tuesday, November 27, 2012
- Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative ColitisLEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the ... read more